Cargando…
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 dea...
Autores principales: | George, Peter M, Wells, Athol U, Jenkins, R Gisli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228727/ https://www.ncbi.nlm.nih.gov/pubmed/32422178 http://dx.doi.org/10.1016/S2213-2600(20)30225-3 |
Ejemplares similares
-
Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022) -
Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19
por: Dhawan, Ranju T, et al.
Publicado: (2021) -
Tachykinins and the potential causal factors for post-COVID-19 condition
por: Janket, Sok-Ja, et al.
Publicado: (2023) -
Sexual dimorphism in COVID-19: potential clinical and public health implications
por: Bechmann, Nicole, et al.
Publicado: (2022) -
Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential
por: Peeling, Rosanna W, et al.
Publicado: (2020)